ITCH polyubiquitinates MLKL at K50

Stable Identifier
R-HSA-9793444
Type
Reaction [omitted]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Under basal conditions, mixed lineage kinase domain-like protein (MLKL) and receptor-interacting serine/threonine-protein kinase 3 (RIPK3) are pre-associated in the cytoplasm (Meng Y et al. 2021). Upon induction of necroptosis the RIPK3:MLKL complex is recruited to the necrosome where RIPK3 phosphorylates and activates MLKL (Meng Y et al. 2021). Studies in human cell lines suggest that phosphorylated MLKL shifts to the plasma membrane and membranous organelles such as mitochondria, lysosome, endosome and ER (Wang H et al. 2014). Its trafficking via a Golgi-microtubule-actin-dependent mechanism facilitates plasma membrane translocation, where membrane disruption causes cell death (Samson AL et al. 2020). However, MLKL also exerts non-necroptotic functions such as regulation of endosomal trafficking or MLKL-induced activation of the NLRP3 inflammasome (Yoon S et al. 2017; Shlomovitz I et al. 2020; Yoon S et al. 2022). In addition, MLKL was shown to mediate myelin breakdown in diabetic neuropathy (Guo J et al. 2022). Activation of MLKL triggers its K63-linked ubiquitination (Yoon S et al. 2022). Conjugation of K63-linked polyubiquitin (pUb) chains in the N-terminal HeLo domain of phosphorylated MLKL targets MLKL to endosomes where MLKL is involved in endosomal compartment trafficking and generation of intraluminal and extracellular vesicles (EV) (Yoon S et al. 2017; Shlomovitz I et al. 2020; Yoon S et al. 2022). Endosome-bound MLKL is excluded from the cell within EV (Yoon S et al. 2022). Mass spectroscopic and western blot assays found that HECT-type E3 ubiquitin-protein ligase Itchy homolog (ITCH) is released within EVs alongside MLKL from human epithelial HT-29 cells in response to combined treatment with the cytokine TNF, the inhibitor of apoptosis proteins (IAP) antagonist BV6, and the caspase inhibitor z-VAD-fmk (TBZ) (Yoon S et al. 2017; 2022). Overexpression of ITCH also dramatically enhanced the association of MLKL with ESCRT proteins. Further, ITCH was shown to interact with MLKL to catalyze K63-linked pUb of MLKL at K50 targeting it to the endosomal membrane (Yoon S et al. 2022). Overexpression of ITCH in TBZ-treated HT-29 cells enhanced the ubiquitination of MLKL, but not of K50R MLKL and also enhanced the association of MLKL with ESCRT proteins (Yoon S et al. 2017; 2022). These data suggest that ITCH catalyzes K63-linked polyubiquitination of MLKL at K50 targeting it to the endosomal membrane, where MLKL is no longer involved in necroptosis but instead has a role in vesicle-mediated trafficking. Further, K63-linked polyUb-MLKL contributes to the host defense against pathogenic bacteria by targeting intracellular bacteria, such as Listeria monocytogenes, Yersinia enterocolitica and Escherichia coli, to endosomal-lysosome trafficking system (Yoon S et al. 2022).

This Reactome event shows ITCH-mediated K63-linked polyubiquitination of MLKL at K50.

Literature References
PubMed ID Title Journal Year
34999730 Site-specific ubiquitination of MLKL targets it to endosomes and targets Listeria and Yersinia to the lysosomes

Wallach, D, Bogdanov, K, Yoon, S

Cell Death Differ 2022
Participants
Participates
Catalyst Activity

ubiquitin-protein transferase activity of p-S-RIPK1:p-S-RIPK3:p-T,S-MLKL:ITCH:Ub:UBE2L3 [cytosol]

Orthologous Events
Authored
Reviewed
Created
Cite Us!